药学学报, 2015, 50(7): 854-860
引用本文:
周琬琪, 张莉婧, 杨瀚泽, 冯志强, 李燕. Aurora激酶抑制剂ZLJ213抗人结肠癌的作用[J]. 药学学报, 2015, 50(7): 854-860.
ZHOU Wan-qi, ZHANG Li-jing, YANG Han-ze, FENG Zhi-qiang, LI Yan. The anti-tumor activity and molecular mechanisms of an Aurora kinase inhibitor ZLJ213 in suppressing colon cancer growth[J]. Acta Pharmaceutica Sinica, 2015, 50(7): 854-860.

Aurora激酶抑制剂ZLJ213抗人结肠癌的作用
周琬琪1, 张莉婧2, 杨瀚泽1, 冯志强2, 李燕1
1. 中国医学科学院、北京协和医学院药物研究所 天然药物活性物质与功能国家重点实验室, 北京 100050;
2. 中国医学科学院、北京协和医学院药物研究所 活性物质发现与适药性北京市重点实验室, 北京 100050
摘要:
ZLJ213是一个定向合成的Aurora激酶及血管内皮生长因子受体 (vascular endothelial growth factor receptor, VEGFR) 双靶点抑制剂。因此, 预计它可以同时抑制肿瘤的增殖及新生血管的生成。本研究通过观察化合物ZLJ213在体外及体内的抗肿瘤作用, 初步探讨其作用机制。研究结果显示, ZLJ213在体外对结肠癌细胞HCT116及SW48有较好的生长抑制作用, 72 h的IC50分别为0.21 μmol·L-1和0.28 μmol·L-1; 明显抑制肿瘤细胞集落的形成, 使细胞周期阻滞在G2/M期, 进而促进结肠癌细胞的凋亡。ZLJ213在100 mg·kg-1剂量下, 可明显抑制人结肠癌HCT116裸鼠异体移植瘤的生长, 抑制率达73.24% (按肿瘤体积计算)。ELISA方法检测到ZLJ213对p-Aurora A的IC50为0.258 μmol·L-1。Western blot结果表明, 0.08 μmol·L-1 ZLJ213可明显抑制p-Aurora A、p-Histone H3及p-VEGFR的表达, 同时下调周期相关蛋白Cyclin B水平, 升高凋亡相关蛋白cleaved Caspase 3和cleaved PARP的水平, 推断ZLJ213有可能是通过抑制Aurora及VEGFR的激酶活性而发挥其抗肿瘤作用。
关键词:    2-(间环丁甲酰氨基苯胺基)-4-(2-环丙甲酰氨基-4-甲基噻唑-5-基) 吡啶      结肠癌      抗肿瘤      Aurora激酶      血管内皮生长因子受体     
The anti-tumor activity and molecular mechanisms of an Aurora kinase inhibitor ZLJ213 in suppressing colon cancer growth
ZHOU Wan-qi1, ZHANG Li-jing2, YANG Han-ze1, FENG Zhi-qiang2, LI Yan1
1. State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2. Beijing Key Laboratory of Active Substance Discovery and Drug Ability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
The aim of this study is to evaluate anti-tumor activities and mechanism of a novel kinase inhibitor ZLJ213 which targeted Aurora A and vascular endothelial growth factor receptor (VEGFR) in vitro and in vivo against human colon cancer. Results showed that ZLJ213 inhibited cell proliferation and induced cell cycle arrest and apoptosis of HCT116 and SW48 cell lines. In HCT116-derived xenograft, ZLJ213 dosed at 100 mg·kg-1 inhibited tumor growth by 73.24%. The IC50 of ZLJ213 on the expression of p-Aurora A was 0.258 μmol·L-1 analyzed by ELISA. Under the concentration of 0.08 μmol·L-1, ZLJ213 could inhibit the activities of Aurora A, Histone H3 and VEGFR of HCT116 and SW48 cell lines. Simultaneously, ZLJ213 induced activation of Caspase 3 and PARP cleavage. Above data suggested that ZLJ213 had the ability to inhibit cell proliferation and induce cell apoptosis both in vitro and in vivo in colon cancer, and down-regulate the expression of p-Aurora A and p-VEGFR. ZLJ213 might be a potential therapeutic agent against colon cancer.
Key words:    2-(m-cyclobutylcarbamoy1-phenylamino)-4-(2-cyclopropylcarbamoyl-4-methylthiazok-5-y1) pyridine    colon cancer    anti-tumor    Aurora kinase    vascular endothelial growth factor receptor   
收稿日期: 2015-03-20
基金项目: 国家自然科学基金青年基金资助项目 (81102025).
通讯作者: 冯志强, 李燕
Email: liyanxiao@imm.ac.cn;fengzhq@imm.ac.cn
相关功能
PDF(2897KB) Free
打印本文
0
作者相关文章
周琬琪  在本刊中的所有文章
张莉婧  在本刊中的所有文章
杨瀚泽  在本刊中的所有文章
冯志强  在本刊中的所有文章
李燕  在本刊中的所有文章

参考文献:
[1] Ke YW, Dou Z, Zhang J, et al. Function and regulation of Aurora/Ipllp kinase family in cell division [J]. Cell Res, 2003, 13: 69-81.
[2] Torchia EC, Zhang L, Hucbner AJ, et al. Aurora kinase A deficiency during skin development impairs cell division and stratification [J]. J Invest Dermatol, 2013, 133: 78-86.
[3] Bolanos-Garcia VM. Aurora kinases [J]. Int J Biochem Cell Biol, 2005, 37: 1572-1577.
[4] Sen S, Katayama H, Sasai K. Functional significance of Aurora kinase A in centrosome amplification and genomic instability [J]. Adv Exp Med Biol, 2008, 617: 99-108.
[5] Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancer [J]. EMBO J, 1998, 17: 3052-3065.
[6] Landen CNJr, Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients [J]. Clin Cancer Res, 2007, 13: 4098-4104.
[7] Tchatchou S, Wirtenberger M, Hemminki K, et al. Aurora kinases A and B and familial breast cancer risk [J]. Cancer Lett, 2007, 247: 266-272.
[8] Chieffi P, Cozzolino L, Kisslinger A, et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation [J]. Prostate, 2006, 66: 326-333.
[9] Jeng YM, Peng SY, Lin CY, et al. Overexpression and amplification of Aurora-A in hepatocellular carcinoma [J]. Clin Cancer Res, 2004, 10: 2065-2071.
[10] Vischioni B, Oudejans JJ, Vos W, et al. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients [J]. Mol Cancer Ther, 2006, 5: 2905-2913.
[11] Tanaka E, Hashimoto Y, Ito T, et al. The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma [J]. Clin Cancer Res, 2005, 11: 1827-1834.
[12] Marumoto T, Zhang D, Saya H. Aurora-A -a guardian of poles [J]. Nat Rev Cancer, 2005, 5: 42-50.
[13] Li D, Zhu J, Firozi PF, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer [J]. Clin Cancer Res, 2003, 9: 991-997.
[14] Wang S, Midgley CA, Scaërou F, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors [J]. J Med Chem, 2010, 53: 4367-4378.
[15] Li Y, Tang K, Zhang LJ, et al. The molecular mechanisms of a nover multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth [J]. Cancer Lett, 2015, 356: 392-403.
[16] Fuller BG, Stukenberg PT. Cell division: righting the check [J]. Curr Biol, 2009, 19: R550-R553.
[17] Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61: 69-90.
[18] Chi XJ, Liu HF, Lan D. Killing effect of cytokine-induced kill cells on colon cancer lines SW-480 in vitro [J]. Guangxi J Med Univ (广西医科大学学报), 2014, 31: 372-377.
[19] Pérez de castro I, de Cárcer G, Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy [J]. Carcinogenesis, 2007, 28: 899-912.
[20] Xia LP, Zhou FF, Yang MT, et al. Roles of Aurora-A in tumorigenesis and prognosis of breast cancer [J]. Chin J Cancer (癌症), 2009, 28: 668-672.
[21] Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy [J]. Clin Cancer Res, 2006, 12: 6869-6875.
[22] Agnese V, Bazan V, Fiorentino FP, et al. The role of Aurora-A inhibitors in cancer therapy [J]. Ann Oncol, 2007, 18 Suppl 6: vi47-vi52.
[23] Traynor AM, Hewitt M, Liu G, et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult with advanced solid tumors [J]. Cancer Chemother Pharmacol, 2011, 67: 305-314.
[24] Kim KW, Mutter RW, Willey CD, et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests [J]. Int J Radiat Oncol Biol Phys, 2007, 67: 1519-1525.
相关文献:
1.刘秀均;李毅;甄永苏;.博安霉素对小鼠结肠癌及其肝转移的抑制作用[J]. 药学学报, 2001,36(1): 14-18
2.宋旭;包明敏;崔大鹏;王真;李电东.抗肿瘤抗生素C1027对人结肠癌HCT 8细胞凋亡相关基因表达的影响[J]. 药学学报, 1999,34(10): 734-738